{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T00:09:40Z","timestamp":1795133380417,"version":"4.10.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cyclin-dependent kinase 4\/6 inhibitors (CDK4\/6i) are the standard of care in advanced breast cancer. While Ki67 is prognostic in early-stage disease, including adjuvant CDK4\/6i, its role in metastatic setting is unclear. This study assessed Ki67\u2019s prognostic value in advanced breast cancer treated with CDK4\/6i.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of patients with advanced breast cancer receiving CDK4\/6i at our cancer center between 2018 and 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 368 patients with Ki67 results. The median age was 63 years (IQR 52\u201370.5). 283 patients (76.9%) received CDK4\/6i in the first-line. With respect to biopsy timing, Ki67 expression was evaluated in tissue samples from 319 patients in the metastatic setting and 49 patients in the early breast cancer setting. In terms of biopsy site, Ki67 was measured from the breast tumor in 235 patients, from regional lymph nodes in 26 patients, and from various metastatic sites in 107 patients. Ki67, as a continuous variable, correlated with PFS and OS. Specifically, each unit increase in Ki67 was associated with a 1% reduction in PFS and OS. Median PFS in patients with lowKi67 was 33.0 months vs. 22.0 months for highKi67 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008). Two-year PFS was 68.3% for lowKi67, vs. 48.4% for highKi67. Median OS was 49.7 months for lowKi67 vs. 39.8 months for highKi67 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.027).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ki67 appears to be a prognostic factor in advanced breast cancer patients treated with CDK4\/6i. Patients with low Ki67 had favorable prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15594-2","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:03:22Z","timestamp":1770987802000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Deciphering the role of Ki67: prognostic insights in advanced breast cancer therapy with Cyclin-dependent kinase 4\/6 inhibitors"],"prefix":"10.1186","volume":"26","author":[{"given":"Marcin","family":"Kubeczko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Polakiewicz-Gilowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"\u015awiderska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mianowska-Malec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Le\u015bniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbarba","family":"\u0141anoszka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstanty","family":"Chomik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Grandys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalya","family":"Lisovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Wo\u017aniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Latusek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Stobiecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Simek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart\u0142omiej","family":"Pyci\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Bobek-Billewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Chmielik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Jarz\u0105b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"15594_CR1","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71:209\u201349.","DOI":"10.3322\/caac.21660"},{"key":"15594_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up \u2606. Ann Oncol. 2024;35:159\u201382.","journal-title":"Ann Oncol"},{"key":"15594_CR3","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","volume":"26","author":"AS Coates","year":"2015","unstructured":"Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart MJ, et al. Tailoring therapies\u2014improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol. 2015;26:1533\u201346.","journal-title":"Ann Oncol"},{"key":"15594_CR4","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/jnci\/djaa201","volume":"113","author":"TO Nielsen","year":"2021","unstructured":"Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, et al. Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst. 2021;113:808\u201319.","journal-title":"J Natl Cancer Inst"},{"key":"15594_CR5","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/S1470-2045(20)30458-7","volume":"21","author":"I Smith","year":"2020","unstructured":"Smith I, Robertson J, Kilburn L, Wilcox M, Evans A, Holcombe C, et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol. 2020;21:1443.","journal-title":"Lancet Oncol"},{"key":"15594_CR6","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1200\/JCO.21.02759","volume":"40","author":"UA Nitz","year":"2022","unstructured":"Nitz UA, Gluz O, K\u00fcmmel S, Christgen M, Braun M, Aktas B, et al. Endocrine therapy response and 21-Gene expression assay for therapy guidance in HR+\/HER2- early breast cancer. J Clin Oncol. 2022;40:2557\u201367.","journal-title":"J Clin Oncol"},{"key":"15594_CR7","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andr\u00e9 F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31:1623\u201349.","journal-title":"Ann Oncol"},{"key":"15594_CR8","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Annals Oncol : Official J Eur Soc Med Oncol. 2021;32:1475\u201395.","journal-title":"Annals Oncol : Official J Eur Soc Med Oncol"},{"key":"15594_CR9","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.annonc.2021.05.353","volume":"32","author":"DJ Slamon","year":"2021","unstructured":"Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol. 2021;32:1015\u201324.","journal-title":"Ann Oncol"},{"key":"15594_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-023-01701-9","volume":"25","author":"P Neven","year":"2023","unstructured":"Neven P, Fasching PA, Chia S, Jerusalem G, De Laurentiis M, Im SA, et al. Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+\/HER2\u2009\u2013\u2009advanced breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer Res. 2023;25:1\u201310.","journal-title":"Breast Cancer Res"},{"key":"15594_CR11","doi-asserted-by":"publisher","first-page":"e1339","DOI":"10.1002\/onco.13833","volume":"26","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Cristofanilli M, Loibl S, Harbeck N, DeMichele A, Iwata H, et al. Prognostic factors for overall survival in patients with hormone Receptor-Positive advanced breast cancer: analyses from PALOMA-3. Oncologist. 2021;26:e1339\u201346.","journal-title":"Oncologist"},{"key":"15594_CR12","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, Node-Positive, High-Risk, early breast cancer (monarchE). J Clin Oncol. 2020;38:3987\u201398.","journal-title":"J Clin Oncol"},{"key":"15594_CR13","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","volume":"390","author":"D Slamon","year":"2024","unstructured":"Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024;390:1080\u201391.","journal-title":"N Engl J Med"},{"key":"15594_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, Toi M, O\u2019Shaughnessy J, Rastogi P, Campone M, Neven P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a Preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:77\u201390.","journal-title":"Lancet Oncol"},{"key":"15594_CR15","first-page":"5230","volume":"27","author":"E Bayram","year":"2023","unstructured":"Bayram E, Selvi O, K\u00f6\u015feci T, Mete B, Yasl\u0131kaya, Payda\u015f S. Comparison of different cyclin-dependent kinase inhibitors and KI-67 levels on survival and toxicity in breast cancer treatment. Eur Rev Med Pharmacol Sci. 2023;27:5230\u20139.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"15594_CR16","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925\u201336.","journal-title":"N Engl J Med"},{"key":"15594_CR17","doi-asserted-by":"crossref","unstructured":"Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. 2019;5:1\u20138.","DOI":"10.1038\/s41523-018-0097-z"},{"key":"15594_CR18","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","volume":"29","author":"GN Hortobagyi","year":"2018","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Annals Oncol : Official J Eur Soc Med Oncol. 2018;29:1541\u20137.","journal-title":"Annals Oncol : Official J Eur Soc Med Oncol"},{"key":"15594_CR19","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-Positive, human epidermal growth factor receptor 2-Negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36:2465\u201372.","journal-title":"J Clin Oncol"},{"key":"15594_CR20","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","volume":"19","author":"D Tripathy","year":"2018","unstructured":"Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19:904\u201315.","journal-title":"Lancet Oncol"},{"key":"15594_CR21","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.annonc.2021.09.015","volume":"32","author":"N Harbeck","year":"2021","unstructured":"Harbeck N, Rastogi P, Martin M, Tolaney SM, Shao ZM, Fasching PA, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarche study. Ann Oncol. 2021;32:1571\u201381.","journal-title":"Ann Oncol"},{"key":"15594_CR22","doi-asserted-by":"crossref","unstructured":"Palleschi M, Maltoni R, Ravaioli S, Vagheggini A, Mannozzi F, Fanini F et al. Ki67 and PR in patients treated with CDK4\/6 inhibitors: A Real-World experience. Diagnostics. 2020;10.","DOI":"10.3390\/diagnostics10080573"},{"key":"15594_CR23","unstructured":"Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Th\u00fcrlimann B et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology. 2013;24:2206\u201323. Available from: https:\/\/www.annalsofoncology.org\/action\/showFullText?pii=S0923753419369649.\u00a0[cited 2025 Aug 6]."},{"key":"15594_CR24","doi-asserted-by":"crossref","unstructured":"Vasconcelos I, Hussainzada A, Berger S, Fietze E, Linke J, Siedentopf F et al. The St. Gallen surrogate classification for breast cancer subtypes successfully predicts tumor presenting features, nodal involvement, recurrence patterns and disease free survival. The Breast. 2016;29:181\u20135. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0960977616301266.\u00a0[cited 2025 Aug 7].","DOI":"10.1016\/j.breast.2016.07.016"},{"key":"15594_CR25","doi-asserted-by":"crossref","unstructured":"Lammers SWM, Geurts SME, Hermans KEPE, Kooreman LFS, Swinkels ACP, Smorenburg CH et al. The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial. ESMO Open. 2025;10:104154. Available from: https:\/\/www.esmoopen.com\/action\/showFullText?pii=S2059702925000225.\u00a0[cited 2025 Aug 7].","DOI":"10.1016\/j.esmoop.2025.104154"},{"key":"15594_CR26","doi-asserted-by":"publisher","unstructured":"Lindman H, Wiklund F, Andersen KK. Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes \u2013 an observational cohort study in Sweden. BMC Cancer. 2022;22:1\u201312. Available from: https:\/\/bmccancer.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s12885-022-10098-1. [cited 2025 Aug 7].","DOI":"10.1186\/s12885-022-10098-1"},{"key":"15594_CR27","doi-asserted-by":"crossref","unstructured":"Wang X, Zhao S, Xin Q, Zhang Y, Wang K, Li M. Recent progress of CDK4\/6 inhibitors\u2019 current practice in breast cancer. Cancer Gene Ther. 2024;31:1283\u201391. Available from: https:\/\/www.nature.com\/articles\/s41417-024-00747-x.\u00a0[cited 2025 Aug 7].","DOI":"10.1038\/s41417-024-00747-x"},{"key":"15594_CR28","doi-asserted-by":"crossref","unstructured":"Tolosa P, Pascual T, Mart\u00ednez-Saez O, Hernando C, Servitja S, Fern\u00e1ndez Abad M et al. Efficacy outcomes of CDK4\/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive\/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study. Eur J Cancer. 2025;217:115219. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0959804924018264.\u00a0[cited 2025 Aug 7].","DOI":"10.1016\/j.ejca.2024.115219"},{"key":"15594_CR29","doi-asserted-by":"crossref","unstructured":"Cristofanilli M, DeMichele A, Giorgetti C, Turner NC, Slamon DJ, Im SA et al. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. European journal of cancer (Oxford, England : 1990). 2018;104:21\u201331.","DOI":"10.1016\/j.ejca.2018.08.011"},{"key":"15594_CR30","doi-asserted-by":"crossref","unstructured":"O\u2019Shaughnessy J, Beck T, Chia S, Isaacs C, De Laurentiis M, Kuemmel S et al. 196P Efficacy and safety of first-line (1L) ribociclib (RIB)\u2009+\u2009letrozole (LET) in patients (pts) with de novo metastatic disease and late recurrence from (neo)adjuvant therapy (tx) in MONALEESA (ML)-2 - ESMO Open [Internet]. ESMO open. 2023 [cited 2024 Feb 16]. p. 101385. Available from: https:\/\/www.esmoopen.com\/article\/S2059-7029(23)00611-7\/fulltext.","DOI":"10.1016\/j.esmoop.2023.101385"},{"key":"15594_CR31","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/oncolo\/oyac089","volume":"27","author":"ES Knudsen","year":"2022","unstructured":"Knudsen ES, Schultz E, Hamilton D, Attwood K, Edge S, O\u2019Connor T, et al. Real-World experience with CDK4\/6 inhibitors for metastatic HR+\/HER2- breast cancer at a single cancer center. Oncologist. 2022;27:646\u201354.","journal-title":"Oncologist"},{"key":"15594_CR32","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus Palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425\u201339.","journal-title":"Lancet Oncol"},{"key":"15594_CR33","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S1470-2045(21)00756-7","volume":"23","author":"G Antonarelli","year":"2022","unstructured":"Antonarelli G, Valenza C, Mayer EL, Loibl S, Curigliano G. Cyclin dependent kinase 4\/6 inhibitors in early breast cancer: what is the role of Ki-67? Lancet Oncol. 2022;23:325\u20138.","journal-title":"Lancet Oncol"},{"key":"15594_CR34","first-page":"1","volume":"477","author":"G Nielsen","year":"2020","unstructured":"Nielsen G, Gu Y, Weaver A, Gegg G, Tabuena-Frolli S, Gruver AM, et al. Development of a novel clinical trial immunohistochemistry (IHC) assay using Ki-67, clone MIB-1, monoclonal antibody for Dako omnis. VIRCHOWS ARCHIV Eur J Pathol. 2020;477:1\u2013390.","journal-title":"VIRCHOWS ARCHIV Eur J Pathol"},{"key":"15594_CR35","doi-asserted-by":"crossref","unstructured":"Sucuo\u011flu \u0130\u015fleyen Z, Mu\u011flu H, Alaca Top\u00e7u Z, Be\u015firo\u011flu M, Yasin A\u0130, Top\u00e7u A et al. Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4\/6 Inhibitors. Medicina. 2025;61:1279. Available from: https:\/\/www.mdpi.com\/1648-9144\/61\/7\/1279\/htm.\u00a0[cited 2025 Aug 7].","DOI":"10.3390\/medicina61071279"},{"key":"15594_CR36","doi-asserted-by":"crossref","unstructured":"Klocker EV, Egle D, Bartsch R, Rinnerthaler G, Gnant M. Efficacy and Safety of CDK4\/6 Inhibitors: A Focus on HR+\/HER2\u2009\u2013\u2009Early Breast Cancer. Drugs. 2025;85:149. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11802638\/.\u00a0[cited 2025 Aug 7].","DOI":"10.1007\/s40265-024-02144-y"},{"key":"15594_CR37","doi-asserted-by":"publisher","unstructured":"Klapp V, Buqu\u00e9 A, Bloy N, Sato A, Yamazaki T, Zhou XK et al. Cellular senescence in the response of HR\u2009+\u2009breast cancer to radiotherapy and CDK4\/6 inhibitors. J Transl Med. 2023;21:1\u201310. Available from: https:\/\/translational-medicine.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s12967-023-03964-4. [cited 2025 Aug 7].","DOI":"10.1186\/s12967-023-03964-4"},{"key":"15594_CR38","doi-asserted-by":"publisher","unstructured":"Liu J, Cheng M, Xu J, Liang Y, Yin B, Liang J. Effect of CDK4\/6 Inhibitors on Tumor Immune Microenvironment. Immunol Invest [Internet]. 2024 [cited 2025 Aug 7];53:437\u201349. Available from: https:\/\/www.tandfonline.com\/doi\/abs\/https:\/\/doi.org\/10.1080\/08820139.2024.2304565","DOI":"10.1080\/08820139.2024.2304565"},{"key":"15594_CR39","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1200\/JCO.20.03639","volume":"39","author":"S Loibl","year":"2021","unstructured":"Loibl S, Marm\u00e9 F, Martin M, Untch M, Bonnefoi H, Kim SB, et al. Palbociclib for residual High-Risk invasive HR-Positive and HER2-Negative early breast Cancer-The Penelope-B trial. J Clin Oncol. 2021;39:1518\u201330.","journal-title":"J Clin Oncol"},{"key":"15594_CR40","doi-asserted-by":"crossref","unstructured":"Reinert T, de Souza ABA, Sartori GP, Obst FM, Barrios CH. Highlights of the 17th St Gallen International Breast Cancer Conference 2021: customising local and systemic therapies. Ecancermedicalscience. 2021;15.","DOI":"10.3332\/ecancer.2021.1236"},{"key":"15594_CR41","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ejca.2017.01.017","volume":"75","author":"MJ Duffy","year":"2017","unstructured":"Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, et al. Clinical use of biomarkers in breast cancer: updated guidelines from the European group on tumor markers (EGTM). Eur J Cancer. 2017;75:284\u201398.","journal-title":"Eur J Cancer"},{"key":"15594_CR42","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1093\/annonc\/mdt350","volume":"24","author":"C Denkert","year":"2013","unstructured":"Denkert C, Loibl S, M\u00fcller BM, Eidtmann H, Schmitt WD, Eiermann W, et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: A translational investigation in the neoadjuvant Gepartrio trial. Ann Oncol. 2013;24:2786\u201393.","journal-title":"Ann Oncol"},{"key":"15594_CR43","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000345795","volume":"84","author":"T Ibrahim","year":"2013","unstructured":"Ibrahim T, Farolfi A, Scarpi E, Mercatali L, Medri L, Ricci M, et al. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact. Oncology. 2013;84:150\u20137.","journal-title":"Oncology"},{"key":"15594_CR44","doi-asserted-by":"publisher","first-page":"1053125","DOI":"10.3389\/fonc.2023.1053125","volume":"13","author":"X Hu","year":"2023","unstructured":"Hu X, Chen W, Li F, Ren P, Wu H, Zhang C, et al. Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance. Front Oncol. 2023;13:1053125.","journal-title":"Front Oncol"},{"key":"15594_CR45","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10549-014-3096-2","volume":"147","author":"C Falato","year":"2014","unstructured":"Falato C, Lorent J, Tani E, Karlsson E, Wright PK, Bergh J, et al. Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer. Breast Cancer Res Treat. 2014;147:407\u201314.","journal-title":"Breast Cancer Res Treat"},{"key":"15594_CR46","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1007\/s12282-017-0774-z","volume":"24","author":"H Inari","year":"2017","unstructured":"Inari H, Suganuma N, Kawachi K, Yoshida T, Yamanaka T, Nakamura Y, et al. Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer. Breast Cancer. 2017;24:748\u201355.","journal-title":"Breast Cancer"},{"key":"15594_CR47","doi-asserted-by":"crossref","unstructured":"Nishimura R, Osako T, Okumura Y, Tashima R, Toyozumi Y, Arima N. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World J Surg Oncol. 2011;9.","DOI":"10.1186\/1477-7819-9-131"},{"key":"15594_CR48","doi-asserted-by":"crossref","unstructured":"Asghar US, Kanani R, Roylance R, Mittnacht S. Systematic review of molecular biomarkers predictive of resistance to CDK4\/6 Inhibition in metastatic breast cancer. JCO Precision Oncol. 2022.","DOI":"10.1200\/PO.21.00002"},{"key":"15594_CR49","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1200\/JCO.20.02977","volume":"39","author":"A Prat","year":"2021","unstructured":"Prat A, Chaudhury A, Solovieff N, Pare L, Martinez D, Chic N, et al. Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA phase III studies. J Clin Oncol. 2021;39:148\u20131467.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15594-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15594-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15594-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:14:20Z","timestamp":1781633660000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15594-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15594"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15594-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments. Ethical approval was obtained from the Institutional Ethics Committee of Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch (approval no. KB\/430\u2009\u2212\u200927\/22). The requirement for informed consent to participate was waived by the Institutional Ethics Committee of Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Marcin Kubeczko declares conference fees for Pfizer, Roche, Novartis, Teva, Amgen, Gilead, Swixx Biopharma, AstraZeneca and MSD; clinical trials for Roche, MSD, Novartis, Seagen, and Gilead; speaker\u2019s honoraria from Novartis, Roche, Lilly, Pfizer, MSD, Teva, Amgen, Swixx Biopharma, AstraZeneca and Gilead; advisory board for Novartis and Gilead; all outside the submitted work. Anna Polakiewicz-Gilowska declares conferences fees for Pfizer, clinical trials for Roche, MSD, Novartis, Seagen, Gilead; speaker\u2019s honorarium: Pfizer, Novartis, Gilead; all outside the submitted work. Katarzyna \u015awiderska declares conferences fees: Novartis, clinical studies: Roche, MSD, Novartis; speaker\u2019s honorarium: Novartis; all outside the submitted work. Aleksandra Le\u015bniak declares conferences fees: Accord, Novartis, clinical studies: Roche, MSD, Novartis; speaker\u2019s honorarium: Novartis; all outside the submitted work. Marta Mianowska-Malec declares conferences fees: Pfizer, Roche, Novartis, Teva, Amgen; clinical studies: Roche, MSD, Novartis; speaker\u2019s honorarium: Novartis, Pfizer; all outside the submitted work. Barbaraba \u0141anoszka declares conferences fees: Pfizer, Roche, Novartis, Teva, Amgen, MSD; clinical studies: Roche, MSD, Novartis; speaker\u2019s honorarium: Novartis, Komtur Care; all outside the submitted work. Konstanty Chomik declares conferences fees: Novartis, clinical studies: Roche, MSD, Novartis; speaker\u2019s honorarium: Lilly; all outside the submitted work. Barbara Grandys: clinical studies: Roche, MSD, Novartis; speaker\u2019s honorarium: Gilead, Novartis; all outside the submitted work. Natalya Lisovska declares clinical trials for Roche, MSD, Seagen, and Gilead; all outside the submitted work. Micha\u0142 Jarz\u0105b declares conference fees for Gilead, Roche; clinical trials for Roche, MSD, Novartis, Seagen, and Gilead; speaker\u2019s honoraria from Novartis, Roche, Lilly, Pfizer, Teva, Exact Sciences, Mammotome, and Gilead; advisory boards for Novartis and Pfizer; all outside submitted work. All other authors declare they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"377"}}